Heron Therapeutics Inc (OQ:HRTX)

Business Focus: Biotechnology & Medical Research

Apr 01, 2019 08:30 ET
Heron Announces European Medicines Agency Validation of Marketing Authorisation Application for HTX-011 for Postoperative Pain Management
SAN DIEGO, April 1, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the Marketing Authorisation Application (MAA) for its investigational agent, HTX-011, for postoperative pain, was validated by the European Medicines Agency (EMA). Validation of the MAA confirms that the submission is complete and starts the EMA's Centralised Procedure. The EMA granted eligibility to the Central...
Mar 11, 2019 08:30 ET
77% of Patients Remain Opioid-Free When HTX-011 Is Given with an Over-the-Counter Analgesic Regimen in New Multi-center Postoperative Pain Management Study in Bunionectomy
SAN DIEGO, March 11, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced results of a multi-center postoperative pain management study in which 31 patients undergoing bunionectomy surgery received the investigational agent, HTX-011, together with a regimen of generic over-the-counter (OTC) oral analgesics (acetaminophen and ibuprofen). Designed as a follow-up to the Phase 3 study in buni...
Mar 05, 2019 07:25 ET
Report: Exploring Fundamental Drivers Behind Caesars Entertainment, Party City Holdco, Rowan Companies, TiVo, Heron Therapeutics, and Cimarex Energy — New Horizons, Emerging Trends, and Upcoming Devel
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Caesars Entertainment Corporation (NASDAQ:CZR), Party City Holdco Inc....
Mar 04, 2019 15:05 ET
Heron Therapeutics to Present at the 39th Annual Cowen Healthcare Conference
SAN DIEGO, March 4, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced that Barry Quart, Pharm.D., President and Chief Executive Officer of Heron Therapeutics, will present at the 39th Annual Cowen Healthcare Conference on Monday, March 11, 2019, at 2:10 p.m. EST at The Boston Marriott Copley Place....
Feb 26, 2019 15:05 ET
Heron Announces FDA Approval of Supplemental New Drug Application to Expand CINVANTI® Label for IV Push
SAN DIEGO, Feb. 26, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the U.S. Food and Drug Administration (FDA) has approved Heron's supplemental New Drug Application (sNDA) for CINVANTI (aprepitant) injectable emulsion, for intravenous (IV) use. The sNDA requested FDA approval to expand the administration of CINVANTI beyond the already approved administration method (a 30-minut...
Feb 22, 2019 07:30 ET
Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2018 and Recent Corporate Progress
SAN DIEGO, Feb. 22, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today reported financial results for the three and twelve months ended December 31, 2018 and highlighted recent corporate progress....
Feb 20, 2019 15:05 ET
Heron Therapeutics to Present at the 8th Annual Leerink Partners Global Healthcare Conference
SAN DIEGO, Feb. 20, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced that Barry Quart, Pharm.D., President and Chief Executive Officer of Heron Therapeutics, will participate in a fireside chat at the 8th Annual Leerink Partners Global Healthcare Conference on Wednesday, February 27, 2019, at 1:00 p.m. EST at the Lotte New York Palace Hotel. ...
Feb 05, 2019 15:30 ET
Heron Therapeutics Announces Retirement of Robert Rosen as President
SAN DIEGO, Feb. 5, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that Robert Rosen, President, will be retiring. Mr. Rosen's responsibilities will be transitioned to Barry Quart, Pharm.D., Chief Executive Officer of Heron, who will take on the additional role of President....
Jan 30, 2019 07:35 ET
New Research Coverage Highlights Heron Therapeutics, IDACORP, Star Bulk Carriers, AngioDynamics, Marinus Pharmaceuticals, and Advaxis — Consolidated Revenues, Company Growth, and Expectations for 2019
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Heron Therapeutics, Inc. (NASDAQ:HRTX), IDACORP, Inc. (NYSE:IDA), Star...
Jan 07, 2019 07:30 ET
Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises
SAN DIEGO, Jan. 7, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today highlighted progress in its pain management and chemotherapy-induced nausea and vomiting (CINV) franchises....
Jan 03, 2019 07:30 ET
90% of Patients Remain Opioid-Free When HTX-011 Is Given with an Over-the-Counter Analgesic Regimen in New Multi-center Postoperative Pain Management Study
SAN DIEGO, Jan. 3, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced results of a multi-center postoperative pain management study in which 63 patients undergoing hernia repair surgery received the investigational agent, HTX-011, together with a regimen of generic over-the-counter (OTC) oral analgesics (acetaminophen and ibuprofen). Designed as a follow-up to the Phase 3 study in herni...
Dec 31, 2018 15:05 ET
Heron Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Dec. 31, 2018 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019, at 5:00 p.m. PST at the Westin St. Francis hotel in San Francisco, CA....
Dec 31, 2018 07:30 ET
FDA Grants Priority Review Designation for Heron Therapeutics' NDA for HTX-011, a Non-Opioid for Postoperative Pain Management
SAN DIEGO, Dec. 31, 2018 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the U.S. Food and Drug Administration (FDA) has accepted the new drug application (NDA) for Heron's investigational agent, HTX-011, and has granted it a Priority Review designation. HTX-011 is a long-acting, extended-release formulation of the local anesthetic bupivacaine in a fixed-dose combination with the ant...
Nov 27, 2018 07:50 ET
Report: Exploring Fundamental Drivers Behind Aclaris Therapeutics, Extreme Networks, Care, Air Lease, Globus Medical, and Heron Therapeutics — New Horizons, Emerging Trends, and Upcoming Developments
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Aclaris Therapeutics, Inc. (NASDAQ:ACRS), Extreme Networks, Inc....
Nov 20, 2018 15:05 ET
Heron Therapeutics to Present at the Evercore ISI HealthCONx Conference
SAN DIEGO, Nov. 20, 2018 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will participate in a fireside chat at the Evercore ISI HealthCONx Conference on Tuesday, November 27, 2018, at 10:15 a.m. EST at the Boston Harbor Hotel. ...
Nov 12, 2018 15:01 ET
U.S. Surgeon General Jerome Adams Discusses Opioid Alternatives and the Importance of Partnerships at Heron Therapeutics
SAN DIEGO, Nov. 12, 2018 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today hosted a fireside chat with the U.S. Surgeon General, Vice Admiral Jerome M. Adams, M.D., M.P.H. It was a familiar venue for Dr. Adams, as he continues to visit communities across the country and advocate for forming non-traditional partnerships with businesses, faith-based communities and law enforcement agencies to tackle th...
Nov 07, 2018 15:05 ET
Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2018 and Recent Corporate Progress
SAN DIEGO, Nov. 7, 2018 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today reported financial results for the three and nine months ended September 30, 2018 and highlighted recent corporate progress....
Oct 31, 2018 16:01 ET
Heron Announces FDA Submission of HTX-011 NDA for Postoperative Pain Management
SAN DIEGO, Oct. 31, 2018 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for HTX-011. HTX-011 is an investigational, long-acting, extended-release formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam for the management of postoperative...
Oct 12, 2018 07:40 ET
Factors of Influence in 2018, Key Indicators and Opportunity within Cloud Peak Energy, Ralph Lauren, CytomX Therapeutics, Extreme Networks, Heron Therapeutics, and Alteryx — New Research Emphasizes Ec
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cloud Peak Energy Inc (NYSE:CLD), Ralph Lauren Corporation (NYSE:RL),...
Sep 24, 2018 16:05 ET
Heron Therapeutics to Present at the 2018 Cantor Global Healthcare Conference
SAN DIEGO, Sept. 24, 2018 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will present at the 2018 Cantor Global Healthcare Conference on Monday, October 1, 2018, at 2:20 p.m. EDT at the Intercontinental New York Barclay Hotel. ...
Aug 13, 2018 08:00 ET
New Research Coverage Highlights East West, Heron Therapeutics, Invacare, CNO Financial Group, Fortinet, and Realogy — Consolidated Revenues, Company Growth, and Expectations for 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of East West Bancorp, Inc. (NASDAQ:EWBC), Heron Therapeutics, Inc....
Aug 08, 2018 08:30 ET
Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2018 and Recent Corporate Progress
SAN DIEGO, Aug. 8, 2018 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today reported financial results for the three and six months ended June 30, 2018 and highlighted recent corporate progress....
Jun 25, 2018 22:01 ET
Heron Therapeutics Announces Pricing of Public Offering of Common Stock
Heron Therapeutics, Inc. (“Heron”) (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the pricing of an underwritten public offering of approximately $200 million of shares of its common stock. In addition, Heron has granted the underwriter of the offering a 30-day option to purchase up to an additional approximately $30 million of shares of its common stock. The offering is expected t
Jun 25, 2018 16:01 ET
Heron Therapeutics Announces Public Offering of Common Stock
Heron Therapeutics, Inc. (“Heron”) (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced an underwritten public offering of approximately $200 million of shares of its common stock. In addition, Heron has granted the underwriter of the offering a 30-day option to purchase up to an additional approximately $30 million of shares of its common stock. All of the shares of common stock in the
Jun 21, 2018 08:05 ET
HTX-011 for Postoperative Pain Management Receives Breakthrough Therapy Designation from FDA
Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that HTX-011 for postoperative pain management has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA). HTX-011 is an investigational, long-acting, extended-release formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammator
Jun 21, 2018 08:00 ET
Heron Announces Positive Topline Results from Phase 2b Clinical Studies of HTX-011 in Total Knee Arthroplasty and Breast Augmentation
Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced positive topline results from two completed Phase 2b studies of HTX-011: Study 209 (local administration in total knee arthroplasty) and Study 211 (instillation or pectoral pocket nerve block in breast augmentation). HTX-011 achieved the primary endpoints in both studies.
May 29, 2018 16:05 ET
Heron Therapeutics to Present at the Jefferies 2018 Healthcare Conference
Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will present at the Jefferies 2018 Healthcare Conference on Tuesday, June 5, 2018, at 2:00 p.m. EDT at the Grand Hyatt New York Hotel.
May 14, 2018 08:10 ET
Analysis: Positioning to Benefit within Advaxis, e.l.f. Beauty, Heron Therapeutics, PVH, Energy Recovery, and A. O. Smith — Research Highlights Growth, Revenue, and Consolidated Results
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Advaxis, Inc. (NASDAQ:ADXS), e.l.f. Beauty Inc. (NYSE:ELF), Heron...
May 10, 2018 08:30 ET
Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2018 and Recent Corporate Progress
Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today reported financial results for the three months ended March 31, 2018 and highlighted recent corporate progress.
May 09, 2018 16:05 ET
Heron Therapeutics to Present at the Bank of America Merrill Lynch 2018 Healthcare Conference
Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will present at the Bank of America Merrill Lynch 2018 Healthcare Conference on Wednesday, May 16, 2018, at 1:00 p.m. PDT at the Encore Hotel in Las Vegas, NV.
Mar 28, 2018 20:53 ET
Heron Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock
Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the pricing of an underwritten public offering of 6 million shares of its common stock, offered at a price of $26.00 per share. Heron Therapeutics, Inc. has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock on the same terms and conditions. All shares of comm
Mar 28, 2018 16:14 ET
Heron Therapeutics Announces Proposed Public Offering of Common Stock
Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that it intends to offer and sell shares of its common stock in an underwritten registered public offering. All of the shares in the offering are to be sold by Heron Therapeutics, Inc. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be co
Mar 21, 2018 16:05 ET
Heron Therapeutics to Present at the 17th Annual Needham Healthcare Conference
Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will present at the 17th Annual Needham Healthcare Conference on Tuesday, March 27, 2018, at 12:45 p.m. EDT at the Westin Grand Central Hotel, New York.
Mar 19, 2018 08:00 ET
Heron Announces Positive Topline Results From Pivotal Phase 3 Clinical Trials of HTX-011 in Bunionectomy and Hernia Repair
Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced positive topline results from its completed Phase 3 studies of the investigational agent HTX-011 in subjects undergoing bunionectomy (Study 301/EPOCH1) and hernia repair (Study 302/EPOCH2). HTX-011 achieved all primary and key secondary endpoints in both Phase 3 trials, demonstrating statistically signif
Mar 06, 2018 16:05 ET
Heron Therapeutics to Present at the 38th Annual Cowen Healthcare Conference
Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will present at the 38th Annual Cowen Healthcare Conference on Monday, March 12, 2018, at 3:30 p.m. EST at the Boston Marriott Copley Place.
Feb 27, 2018 16:15 ET
Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2017 and Recent Corporate Progress
Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today reported financial results for the three and twelve months ended December 31, 2017 and highlighted recent corporate progress.
Feb 12, 2018 16:05 ET
Heron Therapeutics to Present at the 7th Annual Leerink Partners Global Healthcare Conference
Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on developing novel, best-in-class treatments to address some of the most important unmet patient needs, announced that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will participate in a fireside chat at the 7th Annual Leerink Partners Global Healthcare Conference on Wednesday, February 14, 2018, at 1:00 p.m. EST at the Lotte New York Palace Hotel.
Feb 09, 2018 07:45 ET
Research Report Identifies Hill-Rom, Quantum, Heron Therapeutics, Dillard's, LightPath Technologies, and Adesto Technologies with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Feb. 09, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Hill-Rom Holdings Inc (NYSE:HRC), Quantum Corporation...
Jan 08, 2018 08:30 ET
Heron Therapeutics Highlights Progress in CINV and Pain Management Franchises
Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on developing novel, best-in-class treatments to address some of the most important unmet patient needs, today highlighted progress in the Company’s pain management and CINV franchises.
Jan 02, 2018 16:05 ET
Heron Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on developing novel, best-in-class treatments to address some of the most important unmet patient needs, announced that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018, at 5:00 p.m. PST at the Westin St. Francis hotel in San Francisco, CA.
Dec 05, 2017 09:00 ET
Heron Therapeutics Announces Pricing of Public Offering of Common Stock
Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the pricing of an underwritten public offering of $150 million of shares of its common stock. Heron Therapeutics, Inc. has granted the underwriter a 30-day option to purchase up to an additional $22.5 million of shares of common stock. The offering is expected to close on or about December 7, 2017, subje
Dec 04, 2017 16:01 ET
Heron Therapeutics Announces Public Offering of Common Stock
Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced an underwritten public offering of its common stock. The closing price of Heron Therapeutics, Inc.’s common stock on December 1, 2017 was $17.25 per share.
Nov 20, 2017 08:10 ET
Recent Analysis Shows Premier, Quantum, Heron Therapeutics, Dillard's, LightPath Technologies, and Ichor Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Nov. 20, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Premier, Inc. (NASDAQ:PINC), Quantum Corporation (NYSE:QTM),...
Nov 09, 2017 16:05 ET
Heron Therapeutics Announces U.S. FDA Approval of CINVANTI™ (aprepitant) Injectable Emulsion for the Prevention of Acute and Delayed Chemotherapy-Induced Nausea and Vomiting (CINV)
Heron Therapeutics, Inc. (Nasdaq: HRTX) (the Company or Heron), a commercial-stage biotechnology company focused on developing novel, best-in-class treatments to address some of the most important unmet patient needs, today announced that the U.S. Food and Drug Administration (FDA) has approved CINVANTI™ (aprepitant) injectable emulsion, for intravenous infusion. CINVANTI is a substance P/neurokinin-1 (NK1) receptor antagonist, indicated in adults, in combination with other antiemetic agents, for the prevention of acute and del
Nov 08, 2017 16:05 ET
Heron Therapeutics to Present at the Jefferies London Healthcare Conference
Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on developing novel, best-in-class treatments to address some of the most important unmet patient needs, announced that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will present at the Jefferies London Healthcare Conference on Thursday, November 16, 2017, at 4:00 p.m. GMT (11:00 a.m. EST).
Nov 06, 2017 08:30 ET
Heron Therapeutics Reports Financial Results for the Three and Nine Months Ended September 30, 2017 and Recent Corporate Progress
Heron Therapeutics, Inc. (Nasdaq:HRTX) (the Company or Heron), a commercial-stage biotechnology company focused on developing novel, best-in-class treatments to address some of the most important unmet patient needs, today reported financial results for the three and nine months ended September 30, 2017 and highlighted recent corporate progress.
Oct 26, 2017 08:30 ET
Heron Therapeutics Granted FDA Fast Track Designation for HTX-011 to Reduce Postoperative Pain and the Need for Opioid Analgesics for 72 Hours
Heron Therapeutics, Inc. (Nasdaq: HRTX) (the Company or Heron), a commercial-stage biotechnology company focused on developing novel best-in-class treatments to address some of the most important unmet patient needs, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company’s investigational agent, HTX-011, for local administration into the surgical site to reduce postoperative pain and the need for opioid analgesics for 72 hours. Fast Track designation is a process designed to faci
Oct 20, 2017 08:10 ET
Oct 21, 2016 12:00 ET
InvestorsObserver releases covered-call reports for Inovio Pharmaceuticals, Varian Medical Systems, Heron Therapeutics, Chipotle Mexican Grill and Wynn Resorts
CHICAGO, Oct. 21, 2016 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CMG, HRTX, INO, VAR, and WYNN....